Novo Nordisk sales share by therapy area 2021-2023

Published by
Matej Mikulic,
Feb 5, 2024
In both 2021 and 2022, Danish drug manufacturer Novo Nordisk generated four fifths of its total sales in the diabetes care segment. However, in 2023, the diabetes segment decreased four percent, while the obesity segment increased its share from nine to 18 percent. That was mostly due to the strong sales performance of weight loss drug Wegovy.

Novo Nordisk's sales distribution by therapeutic area from 2021 to 2023

© Statista 2024
Download
Show detailed source information?
Register for free
Already a member?
Log in
Source

Use Ask Statista Research Service

Release date

January 2024

Region

Worldwide

Survey time period

2021 to 2023

Supplementary notes

* Calculated based on provided sales figures.

Citation formats
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

    • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 5 people
$959 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts

Statistics on " Novo Nordisk "

The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics

Other statistics that may interest you Novo Nordisk

Global positioning

6

Key metrics

4

Segments

4

Competitors

5

Diabetes - a growing market

6

Further related statistics

20

Further Content: You might find this interesting as well

Statistics

Topics

Novo NordiskGlobal pharmaceutical industryPharmaceutical industry in the U.S.DiabetesDiabetes in China
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

    • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 5 people
$959 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts
Learn more about how Statista can support your business.